Source: China – South China Morning PostChinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.Read More
Source: China – South China Morning PostChinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.Read More